AI chatbot aims to tame diabetes drug side effects
NCT ID NCT07546357
First seen Apr 25, 2026 · Last updated Jun 22, 2026 · Updated 9 times
Summary
This study is testing a new AI-powered tool called AIManage that helps doctors and patients manage medications for diabetes and obesity. The tool provides personalized advice on side effects and dose adjustments. The study is in its early stages, with only 16 participants, and is focused on whether people find the tool useful and easy to use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
New York, New York, 10016, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-driven clinical decision support tool (AIManage)
What this could lead to
If successful, this could lead to a practical AI assistant that helps doctors and patients better manage diabetes and obesity medications, reducing side effects and improving dosing.
What could go wrong
This is a very early, small study (16 participants) focused on gathering feedback on the tool's usability, not on proving it improves health outcomes. The tool may not be widely adopted or effective in real-world settings.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.